

Ursolic acid-enriched kudingcha extractive enhances the antitumor activity of bacteria-mediated cancer immunotherapy

Haixia Xu

Hainan University

Linghua Piao

Hainan Medical University

Xiande Liu (✉ 843089676@qq.com)

Hainan University

Shengnan Jiang

Central South University, Affiliated Haikou Hospital

Research Article

Keywords: BCI, ursolic acid-enriched KDCE, antiangiogenesis, VEGFR2

Posted Date: March 29th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1463583/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Bacteria-mediated cancer immunotherapy (BCI) robustly stimulates the immune system and represses angiogenesis, but tumor recurrence and metastasis commonly occur after BCI. The natural product *Illex kudingcha* C.J Tseng enriched with ursolic acid has anti-cancer activity and could potentially augment the therapeutic effects of BCI. The objective of the present study was to determine potential additive effects of these modalities.

Methods

We investigated the anti-cancer activity of KDCE (Kudingcha extractive) combined with S.t Δ ppGpp in the mice colon cancer models.

Results

In the present study, KDCE combined with S.t Δ ppGpp BCI improved antitumor therapeutic efficacy compared to S.t Δ ppGpp or KDCE alone. KDCE did not prolong bacterial tumor-colonizing time, but enhanced the antiangiogenic effect of S.t Δ ppGpp by downregulating VEGFR2.

Conclusions

Combination therapy with S.t Δ ppGpp and KDCE is a potential cancer therapeutic strategy.

Background

Immunotherapy is the fourth-leading cancer therapy following surgery, radiotherapy, and chemotherapy [1; 2]. Immunological checkpoint therapies, such as CTLA-4, PD-L1, and PD-1, have been approved as a clinical cancer treatments [3], but also have limitations; “cold tumors” have decreased T cell infiltration and decreased antigen mutations, such as in pancreatic and ovarian cancers [4]. In addition, checkpoint therapy could cause autoimmune diseases by overactivating the immune system to attack normal tissues [5]. Bacteria-mediated cancer immunotherapy (BCI) was originally described over a century ago and has significant therapeutic advantages, including i) specific tumor targeting; ii) deep penetration of tumor tissue; iii) triggering robust antitumor immune stimulation; iv) low toxicity to normal tissues; v) lower cost than conventional immunotherapies [6].

Attenuated engineered *Salmonella* has been tested in recent clinical trials [7; 8]. *Salmonella*-mediated cancer immunotherapy profoundly affects the tumor microenvironment through several means: shifting macrophage phenotypes from M2 to M1 via toll-like receptors (TLRs) [9], initiating tumor cell apoptosis

by inducing robust nitric oxide (NO) production in tumor cells [10], and inhibiting angiogenesis by downregulating vascular endothelial growth factor (VEGF) [11]. Angiogenesis has a very important role in tumor growth and metastasis. *Salmonella* combined with an antiangiogenic agents achieves improved therapeutic efficacy [12; 13].

Ilex kudingcha C.J Tseng is herbal tea in China, and bioactive compounds in this natural product have multiple therapeutic effects, including anticancer [14], anti-inflammatory [15], antidiabetic [16], and hypolipidaemic effects [17]. Ursolic acid is a pentacyclic triterpene acid and contributes to the anticancer activity of kudingcha [18]. Ko et al. reported that ursolic acid significantly inhibits cancer progression via phosphorylation of the ERK and AKT[19]. Prior studies also identified that ursolic acid nanoparticle-coated attenuated *Salmonella typhimurium* significantly suppresses tumor growth and metastasis [20].

The present study aimed to determine the combined effects of *Salmonella*-mediated cancer immunotherapy and ursolic acid-enriched kudingcha extractive on antitumor activity in a mouse colon cancer model.

Methods

Plant Material

Ilex kudingcha leaves were collected from Kudingcha Institute (Hainan University, Haikou, Hainan, China) and the state permissions were unnecessary to collect the sample. The plant material was identified by their morphological characteristics by Dr. Guomin Liu from the Kudingcha Institute, Hainan University. One voucher specimen (H. Y. Liang 60355) was deposited at the Kudingcha Institute. Dried leaves were ground and passed through a sieve (24 mesh). Kudingcha powder (100 g) was boiled twice in water. The collected residue was extracted twice with 4 L 100% EtOH for 48 h, then subjected to ultrasound-assisted extraction at 50°C for 30 min. The solvent was removed by rotary evaporation to yield a dry extract, which was dissolved in petroleum ether, evaporated, and freeze-dried to remove organic solvents. The petroleum ether fraction was used for further photochemical analysis and experiments.

HPLC-PDA Analysis

An HPLC-PDA system (Waters Corporation, Milford, MA, USA) consisting of a Waters 600 pump and a 996 PDA detector was used. Analyses were performed using a Waters Sun-Fire C18 column (4.6 × 150 mm, 5 µm). Chromatography conditions were as follows: MeOH: H₂O, 90: 10 to 40: 60 for 40 min; MeOH: H₂O, 40: 60 to 100% MeOH for 1 min; and 100% MeOH for 9 min. The flow rate was 0.1 mL/min; injection volume was 20 µL kudingcha extract (20 mg/mL in petroleum ether); and detection wavelengths were 220, 254, and 280 nm.

Mouse Colon Cancer Model and Bacterial Injection

BalB/c mice (male, 5–6 weeks old) were purchased from Guangdong Experimental Animal Center (Guangzhou, Guangdong, China). Experiments were supervised by the Animal Science and Technology

Ethics Committee of Hainan University. Mice were anesthetized with either 2% isoflurane or ketamine (200 mg/kg). CT-26 cells (1×10^6 , ATCC) cultured in DMEM with 10% FBS (Gibco, USA) were implanted subcutaneously into the right flank to generate colon cancer xenografts. Tumor-bearing mice were randomly divided into four groups ($n = 9/\text{group}$) as follows: PBS, SL Δ ppGpp, KDCE, and SL Δ ppGpp + KDCE. KDCE groups received 1 g/kg KDCE daily via intragastric administration. When tumor volume reached 120–160 mm³, 1×10^7 colony-forming units (CFU) SL Δ ppGpp bacteria were intravenously injected. When tumor volume reached ≥ 1500 mm³, mice were euthanized. Tumor volumes were measured and calculated using the following formula: $(L \times H \times W)/2$ (L: length; W: width; H: height).

Attenuated *Salmonella typhimurium* (S.t Δ ppGpp) carrying the luciferase (Lux) gene was kindly provided by J. J. Min (Institute for Molecular Imaging and Theranostics, Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea) and grown in Luria Bertani medium containing kanamycin (Sigma-Aldrich). Bacteria were stored in 25% glycerol stocks at -80°C.

Bacteria Counting and Optical Bioluminescence Imaging

Tissues, including tumor, liver, lung, and spleen, were collected from mice. Ground tissue was transferred to agar petri dishes and incubated overnight at 37°C. The bacterial number per gram of tissue was calculated by the formula: $Y \times 10^Z \times (1 + X) \times 10/X$ (CFU/g; X: tissue weight; Y: bacterial number on the petri dish; Z: dilution factor).

Tumor-bearing mice were injected through the tail vein with S.t Δ ppGpp Lux in 100 μ L PBS to image bacterial bioluminescence imaging and divided into two treatment groups ($n = 6/\text{group}$): S.t Δ ppGpp Lux and S.t Δ ppGpp Lux + KDCE (intragastric administration 1 g/kg daily). D-luciferin (750 μ g, Caliper, Hopkinton, MA, USA) was intraperitoneally injected, and bioluminescence imaging was then performed using an IVIS 100 (Caliper).

H&E Staining

Liver, spleen, kidney, and lung were removed from euthanized mice and fixed in 4% PFA solution for toxicity evaluation of KDCE + S.t Δ ppGpp. Paraffin sections (10 μ M) were stained with a Hematoxylin and Eosin Staining Kit (C0105, Beyotime) according to the manufacturer's protocol.

Western Blotting

Human Umbilical Vein Endothelial Cells (HUVECs, ATCC) were treated with KDCE (0, 40, 80, 100, 120, and 160 μ g/ml) for 24 h. Protein lysates were separated by 10% SDS-PAGE and transferred to PVDF membranes (Merck, Darmstadt, Germany), which were incubated overnight at 4°C with primary antibodies against VEGFR2 (sc-6251), p-ERK (sc-136521), ERK1/2 (sc514302), AKT1/2/3 (sc56878), p-Akt (sc-293125), and β -actin (sc-69879) (Santa Cruz Biotechnology, Inc., Texas, USA). Membranes were then incubated with secondary antibodies. Protein bands were visualized using a chemiluminescence detection kit (ATTO, Tokyo, Japan) and semi-quantified using Image J Ω (Media Cybernetics, Maryland, USA).

Statistical analyses

Statistical analyses were conducted using the GraphPad Prism 5.0, and $p < 0.05$ was considered statistically significant. Survival analysis was conducted using the Kaplan-Meier method and a log-rank test. All data are expressed as means $\pm$ SEM.

Results

KDCE Ursolic Acid Content

HPLC data indicated that the content of ursolic acid in KDCE was 13.4% (Fig. 1).

Effect of KDCE on Anticancer Activity of BCI

To evaluate the effect of KDCE on the therapeutic efficacy of BCI, SL Δ ppGpp (3×10^7 CFU) was injected into tumor-bearing mice via the tail vein on day 1, followed by intragastric administration of KDCE (1 g/kg) daily from day 2 to day 27. KDCE had antitumor activity, and when combined with SL Δ ppGpp had a strong synergistic effect in suppressing tumor growth (Fig. 2A and B) and increased survival rate (Fig. 2C).

Effect of KDCE on Tumor-Colonizing Bacteria

To determine the effect of KDCE on tumor-colonizing bacteria, bacterial activity was measured by bioluminescence analysis, in which tumor-bearing mice were injected with SL Δ ppGpp-Lux. The bacterial tumor-colonizing time in the SL Δ ppGpp + KDCE group (8 days) was shorter than in the SL Δ ppGpp-only group (10 days) (Fig. 3A).

Subsequently, to determine bacterial distribution in major organs, we collected tumor, lung, liver, and spleen samples from bacteria-injected tumor-bearing mice on days 2 and 6. The tumor-colonizing bacterial number in the SL Δ ppGpp + KDCE group was higher on day 2 but lower on day 6 compared to the SL Δ ppGpp-only group (Fig. 3B).

Toxicity Evaluation of KDCE/BCI Combination Therapy

To evaluate the safety of KDCE/BCI combination therapy, we collected lung, liver, and spleen samples from SL Δ ppGpp-injected tumor-bearing mice on day 6 after KDCE treatment for H&E staining. SL Δ ppGpp + KDCE did not induce toxicity in the liver, spleen, kidney, or lung as compared to other groups (Fig. 4A) but did decrease body weight (Fig. 4B).

KDCE VEGFR2 Downregulation

To determine if the anticancer activity of KDCE was related to suppression of angiogenesis, we measured AKT and ERK phosphorylation and VEGFR2 levels using western blotting in HUVECs. KDCE significantly downregulated VEGFR2 in a dose-dependent manner, but did not affect AKT or ERK phosphorylation (Fig. 5).

Discussions

Salmonella-mediated cancer immunotherapy stimulates immune activation and inhibits angiogenesis by downregulating VEGF [11]. Here, we demonstrated that KDCE enhances the antitumor activity of S.t ΔppGpp-mediated cancer immunotherapy, but does not increase bacterial tumor-colonizing time or number. We postulated that ursolic acid-enriched KDCE could decrease tumor volume by downregulating VEGFR2, limiting bacterial colonization. Several prior studies reported that VEGFR2 downregulation plays important role in suppressing tumor angiogenesis, which is related to suppression of ERK [22; 23; 24] and AKT [25; 26; 27]. However, our findings suggest that KDCE-induced VEGFR2 downregulation is not related to deactivation of the AKT or ERK pathways.

Conclusions

The present study demonstrated that ursolic acid-enriched KDCE enhances the antitumor activity of BCI, which could be mediated by VEGFR2 downregulation and subsequent suppression of angiogenesis. Combined BCI and KDCE treatment is a potential modality for cancer therapy.

Abbreviations

BCI
Bacteria-mediated cancer immunotherapy
KDCE
Kudingcha extractive
VEGFR2
Vascular endothelial growth factor receptor 2.

Declarations

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Acknowledgements

Authors wish to thank Guomin Liu for his excellent technical assistance.

Funding

X. D. L. was supported by the Hainan Province Science and Technology Special Fund, China (ZDYF2022SHFZ041) and the Natural Science Foundation of Hainan Province, China (NO. 821RC529). S. N. J. was supported by the Natural Science Foundation of China (NO. 81960556). L. H. P. was supported by the Natural Science Foundation of Hainan Province, China (NO. 821RC584).

Author information

Haixia Xu ^{a,#}, Linghua Piao ^{b,#}, Xiande Liu ^{a,*}, Sheng-nan Jiang ^{c,*}

^aSchool of Life Sciences, Hainan University, Haikou, China

^bDepartment of Physiology, Hainan Medical University, Haikou, China

^cDepartment of Nuclear Medicine, Central South University, Xiangya School of Medicine, Affiliated Haikou Hospital, Haikou, China

[#] Haixia Xu and Linghua Piao contributed equally to this work.

*Correspondence:

Xiande Liu, Ph.D., 843089676@qq.com, Tel.: +86-152-4895-1522

Address: School of Life Sciences, Hainan University, No. 58 Renmin Avenue, Haikou, 570228, China

Shengnan Jiang, MD, Ph.D., 2669253486@qq.com, Tel.: +86-151-0989-0910

Address: Department of Nuclear Medicine, Central South University, Xiangya School of Medicine, Affiliated Haikou Hospital, No. 43 Renmin Avenue, 570208, Haikou, China

Contributions

H. X. X performed investigation, data analysis, and generated the figures. L. H. P. performed investigation and wrote the manuscript. X. D. L. designed experiments and wrote the manuscript. S. N. J designed experiments and wrote the manuscript.

Competing interests

The authors declare no conflicts of interest.

Ethics declarations

Ethics approval and consent to participate

All the procedures and protocols involving plant were conducted in conformity with WHO Guidelines on Good Agricultural and Harvesting Practices (GAP) for Medicinal Plants (2003) and approved by the Ethic Committee from Hainan University (Haikou, Hainan, China).

Competing interests

The authors declare that they have no competing interests.

References


1. D. Ciardiello, P.P. Vitiello, C. Cardone, G. Martini, T. Troiani, E. Martinelli, and F. Ciardiello, Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. *Cancer treatment reviews* 76 (2019) 22–32.
2. K. Banerjee, S. Kumar, K.A. Ross, S. Gautam, B. Poelaert, M.W. Nasser, A. Aithal, R. Bhatia, M.J. Wannemuehler, B. Narasimhan, J.C. Solheim, S.K. Batra, and M. Jain, Emerging trends in the immunotherapy of pancreatic cancer. *Cancer letters* 417 (2018) 35–46.
3. R. Cristescu, R. Mogg, M. Ayers, A. Albright, E. Murphy, J. Yearley, X. Sher, X.Q. Liu, H. Lu, M. Nebozhyn, C. Zhang, J.K. Lunceford, A. Joe, J. Cheng, A.L. Webber, N. Ibrahim, E.R. Plimack, P.A. Ott, T.Y. Seiwert, A. Ribas, T.K. McClanahan, J.E. Tomassini, A. Loboda, and D. Kaufman, Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science (New York, N.Y.)* 362 (2018).
4. J. Galon, and D. Bruni, Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. *Nature reviews. Drug discovery* 18 (2019) 197–218.
5. M. Binnewies, E.W. Roberts, K. Kersten, V. Chan, D.F. Fearon, M. Merad, L.M. Coussens, D.I. Gabrilovich, S. Ostrand-Rosenberg, C.C. Hedrick, R.H. Vonderheide, M.J. Pittet, R.K. Jain, W. Zou, T.K. Howcroft, E.C. Woodhouse, R.A. Weinberg, and M.F. Krummel, Understanding the tumor immune microenvironment (TIME) for effective therapy. *Nature medicine* 24 (2018) 541–550.
6. Y. Guo, Y. Chen, X. Liu, J.J. Min, W. Tan, and J.H. Zheng, Targeted cancer immunotherapy with genetically engineered oncolytic *Salmonella typhimurium*. *Cancer letters* 469 (2020) 102–110.
7. K. Igarashi, K. Kawaguchi, T. Kiyuna, K. Miyake, M. Miyake, A.S. Singh, M.A. Eckardt, S.D. Nelson, T.A. Russell, S.M. Dry, Y. Li, N. Yamamoto, K. Hayashi, H. Kimura, S. Miwa, H. Tsuchiya, S.R. Singh, F.C. Eilber, and R.M. Hoffman, Tumor-targeting *Salmonella typhimurium* A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. *Biochemical and biophysical research communications* 497 (2018) 1055–1061.
8. S.E. Fritz, M.S. Henson, E. Greengard, A.L. Winter, K.M. Stuebner, U. Yoon, V.L. Wilk, A. Borgatti, L.B. Augustin, J.F. Modiano, and D.A. Saltzman, A phase I clinical study to evaluate safety of orally administered, genetically engineered *Salmonella enterica* serovar Typhimurium for canine osteosarcoma. *Veterinary medicine and science* 2 (2016) 179–190.
9. J.H. Zheng, V.H. Nguyen, S.N. Jiang, S.H. Park, W. Tan, S.H. Hong, M.G. Shin, I.J. Chung, Y. Hong, H.S. Bom, H.E. Choy, S.E. Lee, J.H. Rhee, and J.J. Min, Two-step enhanced cancer immunotherapy with engineered *Salmonella typhimurium* secreting heterologous flagellin. *Sci Transl Med* 9 (2017).
10. T.K. Eisenstein, Implications of *Salmonella*-induced nitric oxide (NO) for host defense and vaccines: NO, an antimicrobial, antitumor, immunosuppressive and immunoregulatory molecule. *Microbes and infection* 3 (2001) 1223–31.
11. W.K. Wang, M.C. Chen, H.F. Leong, Y.L. Kuo, C.Y. Kuo, and C.H. Lee, Connexin 43 suppresses tumor angiogenesis by down-regulation of vascular endothelial growth factor via hypoxic-induced factor-

- 1a. Int J Mol Sci 16 (2014) 439–51.
12. A.G. Niethammer, R. Xiang, J.C. Becker, H. Wodrich, U. Pertl, G. Karsten, B.P. Eliceiri, and R.A. Reisfeld, A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. *Nature medicine* 8 (2002) 1369–75.
13. S. Zhou, C. Gravekamp, D. Bermudes, and K. Liu, Tumour-targeting bacteria engineered to fight cancer. *Nature reviews. Cancer* 18 (2018) 727–743.
14. K. Zhu, G. Li, P. Sun, R. Wang, Y. Qian, and X. Zhao, In vitro and in vivo anti-cancer activities of Kuding tea (*Ilex kudingcha* C.J. Tseng) against oral cancer. *Experimental and therapeutic medicine* 7 (2014) 709–715.
15. J.L. Song, Y. Qian, G.J. Li, and X. Zhao, Anti-inflammatory effects of kudingcha methanol extract (*Ilex kudingcha* C.J. Tseng) in dextran sulfate sodium-induced ulcerative colitis. *Molecular medicine reports* 8 (2013) 1256–62.
16. C. Song, C. Xie, Z. Zhou, S. Yu, and N. Fang, Antidiabetic Effect of an Active Components Group from *Ilex kudingcha* and Its Chemical Composition. *Evidence-based complementary and alternative medicine: eCAM* 2012 (2012) 423690.
17. J. Zheng, H. Zhou, Y. Zhao, Q. Lun, B. Liu, and P. Tu, Triterpenoid-enriched extract of *Ilex kudingcha* inhibits aggregated LDL-induced lipid deposition in macrophages by downregulating low density lipoprotein receptor-related protein 1 (LRP1). *Journal of Functional Foods* 18 (2015) 643–652.
18. R. Yin, T. Li, J.X. Tian, P. Xi, and R.H. Liu, Ursolic acid, a potential anticancer compound for breast cancer therapy. *Critical reviews in food science and nutrition* 58 (2018) 568–574.
19. E.Y. Ko, and A. Moon, Natural Products for Chemoprevention of Breast Cancer. *Journal of cancer prevention* 20 (2015) 223–31.
20. Y. Wu, Q. Li, Y. Liu, Y. Li, Y. Chen, X. Wu, and X. Liu, Targeting hypoxia for sensitization of tumors to apoptosis enhancement through supramolecular biohybrid bacteria. *International journal of pharmaceutics* 605 (2021) 120817.
21. K. Westphal, S. Leschner, J. Jablonska, H. Loessner, and S. Weiss, Containment of tumor-colonizing bacteria by host neutrophils. *Cancer Res* 68 (2008) 2952–60.
22. Q. Zhang, S. Lu, T. Li, L. Yu, Y. Zhang, H. Zeng, X. Qian, J. Bi, and Y. Lin, ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. *Journal of experimental & clinical cancer research: CR* 38 (2019) 173.
23. F. Zhou, F. Liu, J. Liu, Y.L. He, Q.M. Zhou, L. Guo, C. Peng, and L. Xiong, Stachydrine promotes angiogenesis by regulating the VEGFR2/MEK/ERK and mitochondrial-mediated apoptosis signaling pathways in human umbilical vein endothelial cells. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 131 (2020) 110724.
24. W. Wang, Y. Liu, L. You, M. Sun, C. Qu, X. Dong, X. Yin, and J. Ni, Inhibitory effects of Paris saponin I, II, VI and VII on HUVEC cells through regulation of VEGFR2, PI3K/AKT/mTOR, Src/eNOS, PLCy/ERK/MERK, and JAK2-STAT3 pathways. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 131 (2020) 110750.

25. F. Song, B. Hu, J.W. Cheng, Y.F. Sun, K.Q. Zhou, P.X. Wang, W. Guo, J. Zhou, J. Fan, Z. Chen, and X.R. Yang, Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. *Cell death & disease* 11 (2020) 573.
26. B. Li, Y. Zhang, R. Yin, W. Zhong, R. Chen, and J. Yan, Activating CD137 Signaling Promotes Sprouting Angiogenesis via Increased VEGFA Secretion and the VEGFR2/Akt/eNOS Pathway. *Mediators of inflammation* 2020 (2020) 1649453.
27. M. Tanaka, S. Nakamura, M. Maekawa, S. Higashiyama, and H. Hara, ANKFY1 is essential for retinal endothelial cell proliferation and migration via VEGFR2/Akt/eNOS pathway. *Biochemical and biophysical research communications* 533 (2020) 1406–1412.

Figures

A



B




Figure 1

Content of ursolic acid in kudingcha. HPLC chromatograms for ursolic acid standard solution (A) and kudingcha samples (B).




Figure 2

Effect of ursolic acid on S.t Δ ppGpp BDI. (A) Representative images of tumors for each group over time. (B) Tumor volume measurement. (C) Kaplan-Meier survival curve.




Figure 3

Effect of KDCE on tumor-colonizing bacteria. (A) Non-invasive monitoring of bacterial bioluminescence for 12 days. **(B)** Bacterial counts in isolated organs from tumor-bearing mice on days 2 and 6.




Figure 4

Toxicity evaluation of KDCE combined with S.t Δ ppGpp. (A) H&E staining for isolated organs of tumor-bearing mice on day 6 after BCI treatment. **(B)** Body weight on day 27.




Figure 5

KDCE downregulated protein levels of VEGFR2 in Human Umbilical Vein Endothelial Cells (HUVECs), but did not affect p-AKT or p-ERK levels.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [X.pdf](#)